Bone and Endocrine Research Group Royal Hospital for Sick Children

Yorkhill, United Kingdom

Bone and Endocrine Research Group Royal Hospital for Sick Children

Yorkhill, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Malik S.,Bone and Endocrine Research Group Royal Hospital for Sick Children | Malik S.,Royal Hospital for Sick Children | Ahmed S.F.,Bone and Endocrine Research Group Royal Hospital for Sick Children | Wilson M.L.,University of Edinburgh | And 9 more authors.
Journal of Crohn's and Colitis | Year: 2012

Introduction: Adalimumab is used to treat children with Crohn's disease (CD), but the effects of adalimumab on growth in CD have not been studied. Aim: To study growth and disease activity over 12. months (6. months prior to (T-6), baseline (T0) and for 6. months following (T. +. 6) adalimumab). Subjects and methods: Growth and treatment details of 36 children (M: 22) who started adalimumab at a median (10th, 90th) age of 14.7. years (11.3, 16.8) were reviewed. Results: Of 36 cases, 28 (78%) went into remission. Overall 42% of children showed catch up growth, which was more likely in: (i) those who achieved remission (median change in height SDS (δHtSDS) increased from -. 0.2 (-. 0.9, 1.0) at T0 to 0.2 (-. 0.6, 1.6) at T. +. 6, (p. =. 0.007)), (ii) in those who were on immunosuppression δHtSDS increased from -. 0.2 (-. 0.9, 1.0) at T0 to 0.1 (-. 0.8, 1.3) at T. +. 6, (p. =. 0.03) and (iii) in those whose indication for using adalimumab therapy was an allergic reaction to infliximab, median δHtSDS increased significantly from -. 0.3 (-. 0.9, 1.0) at T0 to 0.3 (-. 0.5, 1.6) at T. +. 6, (p. =. 0.02). Median δHtSDS also increased from -. 0.4 (-. 0.8, 0.7) at T0 to 0.0 (-. 0.6, 1.6) at T. +. 6, (p. =. 0.04) in 15 children who were on prednisolone therapy when starting adalimumab. Conclusion: Clinical response to adalimumab therapy is associated with an improvement in linear growth in a proportion of children with CD. Improved growth is more likely in patients entering remission and on immunosuppression but is not solely due to a steroid sparing effect. © 2011.

Loading Bone and Endocrine Research Group Royal Hospital for Sick Children collaborators
Loading Bone and Endocrine Research Group Royal Hospital for Sick Children collaborators